Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. Agios Pharmaceuticals Inc shares valued at $315,091 were sold by Washburn Theodore James Jr. on Sep 05 ’25. At $36.87 per share, Washburn Theodore James Jr. sold 8,546 shares. The insider’s holdings dropped to 868 shares worth approximately $31612.56 following the completion of this transaction.
Also, Scadden David sold 200 shares, netting a total of over 8,000 in proceeds. Following the sale of shares at $40.00 each, the insider now holds 17,603 shares.
Before that, DAVID T. SCADDEN had added 200 shares to its account. In a trade valued at $8,000, the Director bought Agios Pharmaceuticals Inc shares for $40.00 each.
As published in their initiating research note from H.C. Wainwright on February 24, 2025, Agios Pharmaceuticals Inc [AGIO] has been a Buy and the price target has been revised to $58. Analysts at Scotiabank started covering the stock with ‘”a Sector outperform”‘ outlook in a report released in mid October. Earlier on September 27, 2024, Leerink Partners downgraded its rating. Their new recommendation was “a Market perform” for AGIO stock which previously was a “an Outperform”.
Analyzing AGIO Stock Performance
On last trading session, Agios Pharmaceuticals Inc [NASDAQ: AGIO] plunged -0.82% to $36.42. The stock’s lowest price that day was $36.39, but it reached a high of $38.45 in the same session. During the last five days, there has been a surge of approximately 2.07%. Over the course of the year, Agios Pharmaceuticals Inc shares have dropped approximately -22.00%.
Is Agios Pharmaceuticals Inc subject to short interest?
Stocks of Agios Pharmaceuticals Inc saw a sharp rise in short interest on 2025-08-29 jumping by 0.66 million shares to 4.76 million. Data from Yahoo Finance shows that the short interest on 2025-07-31 was 4.1 million shares. A jump of 13.88% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 5.25 of the overall float, the days-to-cover ratio (short ratio) jumped to 5.25.
Which companies own the most shares of Agios Pharmaceuticals Inc (AGIO)?
In terms of Agios Pharmaceuticals Inc share price expectations, FactSet research, analysts set an average price target of 71 in the next 12 months, up nearly 93.36% from the previous closing price of $36.72. Analysts anticipate Agios Pharmaceuticals Inc stock to reach 71 by 2025, with the lowest price target being 71. In spite of this, 5 analysts ranked Agios Pharmaceuticals Inc stock as Buy at the end of 2025.
